Yazmin Carrasco, PhD

Assistant Director - SF BUILD at UCSF

I obtained my BS in Chemistry at the University of Texas at El Paso, this in part was possible for science programs like MARC and RISE that help paved my journey in the sciences. From here I moved to Dallas, TX where I did my PhD at UT Southwestern Medical Center working on the isolation of therapeutically interesting natural products from marine bacteria. From there I moved to San Francisco, CA and started my postdoctoral studies at UCSF as part of the IRACDA program where I focused on utilizing small molecules as probes to understand a pathway, that that is essential for numerous cancers to survive. Throughout my scientific journey I always immersed myself on activities aimed at increasing diversity which is something that I am passionate about and I want my future to be an extension of this path.
Education
Postdoctoral Scholar, 2017 - Chemical Biology, UCSF
Ph.D., 2013 - Chemistry, UT Southwestern Medical Center
B.S., 2007 - Chemistry, University of Texas at El Paso
Honors and Awards
  • UCSF's-IRACDA "Scholars for Teaching, Research,Institutional Diversity, and Excellence" (STRIDE), UCSF, 2013-2017
  • Leita Marsh Pharmacological Award, UT Southwestern Medical Center, 2013
  • UT Southwestern’s Excellence in Chemistry Symposium, UT Southwestern Medical Center, 2013
  • Carl Storm Underrepresented Minority (CSURM) Fellowship, UT Southwestern Medical Center, 2011
  • Taihi Hong Memorial Graduate Student Education award, UT Southwestern Medical Center, 2011
  • Excellence in research oral presentation prize at UT Southwestern’s Simmons Comprehensive Cancer Ctr, UT Southwestern Medical Center, 2011
  • Cancer Prevention Research Institute of Texas (CPRIT) training grant, UT Southwestern Medical Center, 2010-2013
  • Research Initiative for Scientific Enhancement (RISE) Fellowship, UTEP, 2007
  • Minority Access to Research Careers-Undergraduate Student Training for Academic Research (MARC), UTEP, 2005-2007
Publications
  1. Rifamycin Biosynthetic Congeners: Isolation and Total Synthesis of Rifsaliniketal and Total Synthesis of Salinisporamycin and Saliniketals A and B.
  2. Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.
  3. Using functional signature ontology (FUSION) to identify mechanisms of action for natural products.
  4. Nuclear export inhibition through covalent conjugation and hydrolysis of Leptomycin B by CRM1.
  5. Cytotoxic effects of two organotin compounds and their mode of inflicting cell death on four mammalian cancer cells.